PANITUMUMAB
Cancer of Prostate
University of Torontomonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Cancer of Prostate cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sipuleucel-T Roswell Park Cancer Institute | Phase 2 | B |
Metformin Swiss Cancer Institute | Phase 2 | B |
SEPANTRONIUM | Phase 2 | B |
Degarelix Cancer Research Antwerp | Phase 2 | CCC |
TEONANACATL Psyence Australia Pty Ltd | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
PANITUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →